Bronchitol available to named patients

Pharmaxis (ASX: PXS) will soon be distributing its Bronchitol drug on a named patient basis through UK company IDIS.

Under the arrangement doctors can - through IDIS - prescribe Bronchitol to patients not currently undergoing clinical trials of the drug.

Patients who participate in a named patient program are warned that a drug may have unexpected side-effects, and their doctors are generally indemnified from liability as a result of this disclaimer.

The programs are generally used to allow patients with chronic illnesses access to drugs which can potentially help even in countries where the drug has not yet been cleared for sale. It is particularly used in cases where there is no satisfactory alternative available.

Bronchitol is an inhalant spray aimed at cystic fibrosis and bronchiectasis.